Pharmaceutical

MaxCyte and Kamau Therapeutics sign platform license agreement

MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.

Sep 18, 2024 - 04:00
MaxCyte and Kamau Therapeutics sign platform license agreement
MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.
Read the original article

Tags:

Previous Article

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

Next Article

Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA denies approval for Theratechnologies’ tesamorelin F8

FDA denies approval for Theratechnologies’ tesamorelin F8

Jan 25, 2024

Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint

Transgene’s stock drops after Phase II cancer jab trial...

Oct 16, 2024

STAT+: Pharmalittle: CVS to overhaul how it’s paid for drugs; Biden drug-shortage plan won’t expand chemo supplies

STAT+: Pharmalittle: CVS to overhaul how it’s paid for ...

Dec 5, 2023